COLORECTAL CARCINOMA
Clinical trials for COLORECTAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new COLORECTAL CARCINOMA trials appear
Sign up with your email to follow new studies for COLORECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a liver drug tame polyps in rare gut condition?
Disease control TerminatedThis study tested whether obeticholic acid, a drug already used for liver disease, can safely reduce the number of polyps in the small bowel and colon in people with familial adenomatous polyposis (FAP). FAP is a rare genetic condition that greatly raises the risk of intestinal c…
Matched conditions: COLORECTAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental combo for advanced colon cancer shows early promise but trial halted
Disease control TerminatedThis study tested a combination of two drugs, VB-111 and nivolumab, in 14 adults with colorectal cancer that had spread to the liver. The goal was to see if the treatment was safe and could shrink tumors. The trial was terminated early, but researchers collected data on side effe…
Matched conditions: COLORECTAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cancer drug shows early promise, but trial cut short
Disease control TerminatedThis early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…
Matched conditions: COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Pfizer's new cancer combo shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…
Matched conditions: COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC